Aromatasis

Cave: notitiae huius paginae nec praescriptiones nec consilia medica sunt.

Aromatasis (abbreviatura ARO) sive oestrogeni synthetasis sive oestrogeni synthasis sive CYP19A1 (Numerus EC: 1.14.14.1) est enzymum principale ad oestrogena ex androgenis generandum.

Simul ARO vocitatur CYP19A1, quod indicat, ut gregis cytochromatum P450 sit, scilitet haemothiolati monooxygenasum^[1]. Enzymum invenitur in reticulis endoplasmaticis cellularum.

Effectus aromatasis enzymi sunt in feminis crescentia sexualis, et omnibus generibus crescentia in genere.

Multi polymorphismi, varietates geni, descripti sunt. Praeterea mutationes functionis aromatasis syndromas peculiarias ostendunt, generatim functio excessiva in habitum femininum oestrogenis nimiis, impedimentum in masculinum androgenis.

Inhibitio enzymi aromatasis in tractandis cancris mammae momentum habet (aromatasis inhibitores). Diversae inhibitores descriptae sunt^[2].

Natura aromatasis[recensere | fontem recensere]

Genetica[recensere | fontem recensere]

Genum aromatasis CYP19A1 vocatur, chromosomate decimo quinto (15q21.2, coordinata genomica: 15:51,208,056-51,338,597) locatum est. Magnitudo ARO est plus quam septuaginta kilobases^[3].

Natura biochemica[recensere | fontem recensere]

ARO ex androgenis oestrogena generat.

Mutationes functionis aromatasis[recensere | fontem recensere]

Descriptum est syndroma deficientium (deficientia aromatasis, OMIM:613546) malum recessivum (chromosomate 15, autosomate), quo fabricatio oestrogeni vilis vel minuta est, quo fit, ut incremento testosteroni causa iam in utero fetus at enim mater virilizationem ostendunt: pseudohermaphroditismum fetûs feminini, ac matres hirsutismum et acnem^[4]. Prolis habitus statura tenui et magna crescent.
Vice versa syndroma aromatasis excessiva (AEXS, 'OMIM: 139300) cum gynaecomastia notum est.

Inhibitores aromatasis[recensere | fontem recensere]

Notae[recensere | fontem recensere]

↑ Parween S., DiNardo G., Baj F., Zhang C., Gilardi G., Pandey A. V. (2020). "Differential effects of variations in human P450 oxidoreductase on the aromatase activity of CYP19A1 polymorphisms R264C and R264H". The journal of steroid biochemistry and molecular biology (196) doi:10.1016/j.jsbmb.2019.105507
↑ Balunas MJ1, Su B, Brueggemeier RW, Kinghorn AD (2008). "Natural products as aromatase inhibitors". Anticancer Agents Med Chem 8 (6): 646-82
↑ Toda K1, Terashima M, Kawamoto T, Sumimoto H, Yokoyama Y, Kuribayashi I, Mitsuuchi Y, Maeda T, Yamamoto Y, Sagara Y, et al. (1990). "Structural and functional characterization of human aromatase P-450 gene". Eur J Biochem 193 (2): 559-65
↑ Unal E, Yıldırım R, Taş FF, Demir V, Onay H, Haspolat YK (2018). "Aromatase Deficiency due to a Novel Mutation in CYP19A1 Gene". J Clin Res Pediatr Endocrinol
↑ Leder B. Z., Finkelstein J. S. (2005). "Effect of aromatase inhibition on bone metabolism in elderly hypogonadal men". Osteoporos Int 16 (12): 1487-94

Nexus interni

[1] Parween S., DiNardo G., Baj F., Zhang C., Gilardi G., Pandey A. V. (2020). "Differential effects of variations in human P450 oxidoreductase on the aromatase activity of CYP19A1 polymorphisms R264C and R264H". The journal of steroid biochemistry and molecular biology (196) doi:10.1016/j.jsbmb.2019.105507

[2] Balunas MJ1, Su B, Brueggemeier RW, Kinghorn AD (2008). "Natural products as aromatase inhibitors". Anticancer Agents Med Chem 8 (6): 646-82

[3] Toda K1, Terashima M, Kawamoto T, Sumimoto H, Yokoyama Y, Kuribayashi I, Mitsuuchi Y, Maeda T, Yamamoto Y, Sagara Y, et al. (1990). "Structural and functional characterization of human aromatase P-450 gene". Eur J Biochem 193 (2): 559-65

[4] Unal E, Yıldırım R, Taş FF, Demir V, Onay H, Haspolat YK (2018). "Aromatase Deficiency due to a Novel Mutation in CYP19A1 Gene". J Clin Res Pediatr Endocrinol

[5] Leder B. Z., Finkelstein J. S. (2005). "Effect of aromatase inhibition on bone metabolism in elderly hypogonadal men". Osteoporos Int 16 (12): 1487-94

[1]

[2]

[3]

[4]

[5]